Table 1.
Variables | N | Percent | Tamoxifen or AI use, No. (%)a | Pb | |
---|---|---|---|---|---|
No (%) | Yes (%) | ||||
Total | 2871 | 100 | 1574 ( 54.8 ) | 1297 ( 45.2 ) | |
Age, years | |||||
66-70 | 984 | 34.3 | 460 ( 46.7 ) | 524 ( 53.3 ) | <.0001 |
71-75 | 877 | 30.5 | 467 ( 53.2 ) | 410 ( 46.8 ) | |
76-80 | 644 | 22.4 | 403 ( 62.6 ) | 241 ( 37.4 ) | |
81-85 | 366 | 12.7 | 244 ( 66.7 ) | 122 ( 33.3 ) | |
Race/ethnicity | |||||
White | 2277 | 79.3 | 1273 ( 55.9 ) | 1004 ( 44.1 ) | 0.0003 |
Hispanic | 207 | 7.2 | 92 ( 44.4 ) | 115 ( 55.6 ) | |
Black | 248 | 8.6 | 120 ( 48.4 ) | 128 ( 51.6 ) | |
Other | 139 | 4.8 | 89 ( 64.0 ) | 50 ( 36.0 ) | |
Marital status | |||||
Married | 1294 | 45.1 | 669 ( 51.7 ) | 625 ( 48.3 ) | 0.005 |
Not married | 1370 | 47.7 | 794 ( 58.0 ) | 576 ( 42.0 ) | |
Unknown | 207 | 7.2 | 111 ( 53.6 ) | 96 ( 46.4 ) | |
Education level | |||||
1st quartilec | 702 | 24.5 | 414 ( 59.0 ) | 288 ( 41.0 ) | <.0001 |
2nd quartile | 690 | 24 | 413 ( 59.9 ) | 277 ( 40.1 ) | |
3rd quartile | 673 | 23.4 | 361 ( 53.6 ) | 312 ( 46.4 ) | |
4th quartile | 769 | 26.8 | 368 ( 47.9 ) | 401 ( 52.1 ) | |
Unknown | 37 | 1.3 | 18 ( 48.6 ) | 19 ( 51.4 ) | |
Income level | |||||
1st quartiled | 722 | 25.1 | 361 ( 50.0 ) | 361 ( 50.0 ) | 0.004 |
2nd quartile | 682 | 23.8 | 379 ( 55.6 ) | 303 ( 44.4 ) | |
3rd quartile | 691 | 24.1 | 384 ( 55.6 ) | 307 ( 44.4 ) | |
4th quartile | 682 | 23.8 | 406 ( 59.5 ) | 276 ( 40.5 ) | |
Unknown | 94 | 3.3 | 44 ( 46.8 ) | 50 ( 53.2 ) | |
Year of cancer diagnosis | |||||
2007 | 468 | 16.3 | 234 ( 50.0 ) | 234 ( 50.0 ) | 0.11 |
2008 | 553 | 19.3 | 307 ( 55.5 ) | 246 ( 44.5 ) | |
2009 | 576 | 20.1 | 311 ( 54.0 ) | 265 ( 46.0 ) | |
2010 | 589 | 20.5 | 343 ( 58.2 ) | 246 ( 41.8 ) | |
2011 | 685 | 23.9 | 379 ( 55.3 ) | 306 ( 44.7 ) | |
Tumor gradee | |||||
I | 381 | 13.3 | 216 ( 56.7 ) | 165 ( 43.3 ) | 0.64 |
II | 1132 | 39.4 | 606 ( 53.5 ) | 526 ( 46.5 ) | |
III | 835 | 29.1 | 465 ( 55.7 ) | 370 ( 44.3 ) | |
IV | 151 | 5.3 | 88 ( 58.3 ) | 63 ( 41.7 ) | |
Unknown | 372 | 13 | 199 ( 53.5 ) | 173 ( 46.5 ) | |
Tumor size | |||||
≤10 mm | 1130 | 39.4 | 624 ( 55.2 ) | 506 ( 44.8 ) | 0.46 |
>10mm | 952 | 33.2 | 532 ( 55.9 ) | 420 ( 44.1 ) | |
Unknown | 789 | 27.5 | 418 ( 53.0 ) | 371 ( 47.0 ) | |
Surgery and radiation treatment | |||||
LRT | 1601 | 55.8 | 727 ( 45.4 ) | 874 ( 54.6 ) | <.0001 |
Lumpectomy | 583 | 20.3 | 391 ( 67.1 ) | 192 ( 32.9 ) | |
Mastectomy | 687 | 23.9 | 456 ( 66.4 ) | 231 ( 33.6 ) | |
Charlson comorbidity score | |||||
0 | 1810 | 63 | 978 ( 54.0 ) | 832 ( 46.0 ) | 0.28 |
1 | 664 | 23.1 | 364 ( 54.8 ) | 300 ( 45.2 ) | |
>1 | 397 | 13.8 | 232 ( 58.4 ) | 165 ( 41.6 ) | |
Cancer registry | |||||
Connecticut | 137 | 4.8 | 70 ( 51.1 ) | 67 ( 48.9 ) | <.0001 |
Detroit | 123 | 4.3 | 52 ( 42.3 ) | 71 ( 57.7 ) | |
Hawaii | 23 | 0.8 | 12 ( 52.2 ) | 11 ( 47.8 ) | |
Iowa | 199 | 6.9 | 114 ( 57.3 ) | 85 ( 42.7 ) | |
New Mexico | 35 | 1.2 | 23 ( 65.7 ) | 12 ( 34.3 ) | |
Seattle | 121 | 4.2 | 86 ( 71.1 ) | 35 ( 28.9 ) | |
Utah | 46 | 1.6 | 22 ( 47.8 ) | 24 ( 52.2 ) | |
Kentucky | 159 | 5.5 | 88 ( 55.3 ) | 71 ( 44.7 ) | |
Louisiana | 130 | 4.5 | 53 ( 40.8 ) | 77 ( 59.2 ) | |
New Jersey | 373 | 13 | 215 ( 57.6 ) | 158 ( 42.4 ) | |
Texas | 468 | 16.3 | 244 ( 52.1 ) | 224 ( 47.9 ) | |
Georgia | 318 | 11.1 | 152 ( 47.8 ) | 166 ( 52.2 ) | |
California | 739 | 25.7 | 443 ( 59.9 ) | 296 ( 40.1 ) |
Abbreviations: AI, aromatase inhibitor; LRT, lumpectomy followed by radiation therapy.
Row percentages for each stratum are shown.
P values for age, education level, income level, year of cancer diagnosis, tumor grade, and tumor size were determined with the Cochran-Armitage trend test; other P values were determined with the chi-square test.
Highest percentage of residents who graduated from high school
Highest median household income
Grade I is well differentiated, grade II is moderately differentiated, grade III is poorly differentiated, and grade IV is undifferentiated.